New strategies to target Bcr-Abl with ATP-competitive and allosteric inhibitors

被引：0
|
作者：
Hantschel, O. [1 ]
机构：
[1] Ecole Polytech Fed Lausanne, Swiss Inst Expt Canc Res ISREC, Lausanne, Switzerland
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：199 / 199
页数：1
相关论文
共 50 条
  • [31] New Insights Into Small-Molecule Inhibitors of Bcr-Abl
    Schenone, S.
    Bruno, O.
    Radi, M.
    Botta, M.
    MEDICINAL RESEARCH REVIEWS, 2011, 31 (01) : 1 - 41
  • [32] Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors
    Kristin M. Zimmerman Savill
    Brian B. Lee
    Jason Oeh
    Jie Lin
    Eva Lin
    Wei-Jen Chung
    Amy Young
    Wennie Chen
    Monika Miś
    Kathryn Mesh
    Jeffrey Eastham
    Florian Gnad
    Zhaoshi Jiang
    Eric W. Stawiski
    Benjamin Haley
    Anneleen Daemen
    Xiaojing Wang
    Hartmut Koeppen
    Zora Modrusan
    Scott E. Martin
    Deepak Sampath
    Kui Lin
    Nature Communications, 13
  • [33] Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors
    Savill, Kristin M. Zimmerman
    Lee, Brian B.
    Oeh, Jason
    Lin, Jie
    Lin, Eva
    Chung, Wei-Jen
    Young, Amy
    Chen, Wennie
    Mis, Monika
    Mesh, Kathryn
    Eastham, Jeffrey
    Gnad, Florian
    Jiang, Zhaoshi
    Stawiski, Eric W.
    Haley, Benjamin
    Daemen, Anneleen
    Wang, Xiaojing
    Koeppen, Hartmut
    Modrusan, Zora
    Martin, Scott E.
    Sampath, Deepak
    Lin, Kui
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [34] Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors
    Lee, B. J.
    Shah, N. P.
    LEUKEMIA, 2017, 31 (05) : 1096 - 1107
  • [35] Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors
    B J Lee
    N P Shah
    Leukemia, 2017, 31 : 1096 - 1107
  • [36] Off-Target Effects of BCR-ABL and JAK2 Inhibitors
    Green, Myke R.
    Newton, Michael D.
    Fancher, Karen M.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01): : 76 - 84
  • [37] Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
    Hyewon Lee
    Igor Novitzky Basso
    Dennis Dong Hwan Kim
    International Journal of Hematology, 2021, 113 : 632 - 641
  • [38] Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
    Lee, Hyewon
    Basso, Igor Novitzky
    Kim, Dennis Dong Hwan
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (05) : 632 - 641
  • [39] Osteopontin is a target of BCR-ABL oncogene.
    Flamant, S
    Kortulewski, T
    Dugray, A
    Bonnet, ML
    Guillier, M
    Guilhot, F
    Bourhis, JH
    Vainchenker, W
    Le Roux, D
    Turhan, AG
    BLOOD, 2003, 102 (11) : 139A - 139A
  • [40] Mechanisms of Resistance to BCR-ABL Kinase Inhibitors
    Diamond, Joana
    da Silva, Maria Gomes
    ACTA MEDICA PORTUGUESA, 2013, 26 (04): : 402 - 408
12345